LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Does GLP-1 expire after 28 days? The answer depends on which GLP-1 receptor agonist you're using and whether it's a multi-dose pen or single-dose device. Medications like Ozempic, Wegovy, Victoza, Saxenda, Trulicity, Mounjaro, and Zepbound each follow different expiration timelines ranging from 14 to 56 days. Understanding these specific storage requirements is essential for maintaining medication efficacy and ensuring safe diabetes or weight management treatment. This guide clarifies FDA-approved expiration guidelines for each GLP-1 medication, proper storage practices, and what happens if you use medication beyond recommended timeframes.
Quick Answer: GLP-1 medications do not all expire after 28 days; expiration timelines vary by product from 14 to 56 days depending on the specific medication and whether it's a multi-dose pen or single-dose device.
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications used primarily for type 2 diabetes management and, in some formulations, for chronic weight management. These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound). Understanding proper storage and expiration guidelines is essential for maintaining medication efficacy and patient safety.
GLP-1 medications are biologic peptides that require specific storage conditions to maintain their structural integrity and therapeutic effectiveness. Unlike many oral medications that remain stable at room temperature for extended periods, GLP-1 receptor agonists are sensitive to temperature fluctuations, light exposure, and time. The FDA-approved prescribing information for each GLP-1 medication provides detailed storage requirements that differ between products.
It's important to distinguish between multi-dose pens (Ozempic, Victoza, Saxenda) and single-dose autoinjectors (Wegovy, Trulicity, Mounjaro, Zepbound). For multi-dose pens, expiration timelines refer to the period after first use, while single-dose devices must be discarded immediately after injection. The commonly referenced timeframes (28, 30, or 56 days) apply differently depending on the specific product and whether it's a multi-dose or single-dose device.
Unopened GLP-1 medications stored properly in the refrigerator remain viable until the manufacturer's printed expiration date, which is typically months or years from the production date. Once a multi-dose pen is first used, or when a single-dose device is removed from refrigeration, different rules apply based on the specific product.
Healthcare providers should educate patients about these storage requirements during initial prescribing and reinforce them at follow-up visits. Proper medication storage directly impacts treatment outcomes, as degraded medication may deliver subtherapeutic doses, potentially leading to inadequate glycemic control or insufficient weight management effects.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
The answer depends on the specific GLP-1 medication and whether it's a multi-dose pen or a single-dose device. Not all GLP-1 receptor agonists follow the same timeline, and storage temperature significantly affects stability.
Multi-dose pens (discard after specified days following first use):
Semaglutide (Ozempic): According to FDA labeling, once in use, Ozempic pens may be stored at room temperature (59°F to 86°F or 15°C to 30°C) or in the refrigerator for up to 56 days.
Liraglutide (Victoza, Saxenda): These formulations follow a 30-day rule after first use. Once a Victoza or Saxenda pen is used for the first time, it should be discarded after 30 days, regardless of whether medication remains in the pen. The pen may be stored at room temperature (up to 86°F or 30°C) or refrigerated during this 30-day period.
Single-dose devices (discard immediately after injection; room temperature allowances apply before use only):
Semaglutide (Wegovy): Wegovy is a single-dose device that must be discarded after injection. Before use, it may be stored at room temperature (up to 86°F or 30°C) for up to 28 days.
Dulaglutide (Trulicity): Trulicity is a single-dose autoinjector that must be discarded after injection. Before use, it can be stored at room temperature (up to 86°F or 30°C) for up to 14 days after removal from refrigeration.
Tirzepatide (Mounjaro, Zepbound): These are single-dose devices that must be discarded after injection. Before use, they may be stored at room temperature (up to 86°F or 30°C) for up to 21 days.
Patients using multi-dose pens should write the date of first use on their pen and set reminders for disposal. For single-dose devices kept at room temperature before use, patients should note the date removed from refrigeration. Using medication beyond the manufacturer's recommended timeframe may result in reduced potency, even if the solution appears normal.
Using GLP-1 medication beyond the manufacturer's recommended timeframe poses several potential risks, though the specific concerns vary by product.
Reduced efficacy is the primary concern. GLP-1 receptor agonists are peptide molecules that gradually degrade over time, particularly when exposed to temperatures outside the recommended range or when stored for extended periods after opening. When medication potency decreases, patients with type 2 diabetes may experience inadequate glycemic control, with blood glucose levels rising above target ranges. For those using GLP-1 medications for weight management, reduced efficacy may manifest as weight loss plateau or regain.
Sterility concerns also arise with multi-dose pens used beyond recommended timeframes. Each injection creates a potential entry point for bacterial contamination. While pens are designed with safety mechanisms, extended use increases contamination risk, particularly if the pen is not stored properly or if injection technique is suboptimal.
According to FDA-approved labeling, the potency and sterility of GLP-1 medications cannot be assured beyond the recommended timeframes. The specific consequences depend on how far beyond the expiration the medication is used and the storage conditions maintained.
Patients who inadvertently use medication beyond the recommended timeframe should contact their healthcare provider. The provider may recommend checking blood glucose levels more frequently (for diabetes patients) or monitoring for other signs of inadequate treatment response. Patients should never extend medication use intentionally to save costs; patient assistance programs and alternative formulations may provide more appropriate solutions.
If you discover you've been using expired GLP-1 medication, don't panic, but do contact your healthcare provider for guidance on appropriate monitoring and potential treatment adjustments.
Proper storage of GLP-1 medications begins before first use and continues throughout the medication's lifespan. Following manufacturer guidelines ensures optimal medication stability and therapeutic effect.
Before first use: All GLP-1 medications should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) until first use or until the manufacturer's expiration date. Store pens in their original carton to protect from light. Do not freeze GLP-1 medications; freezing permanently damages the peptide structure, rendering the medication ineffective. If a pen has been frozen, it must be discarded, even if it later thaws. Keep pens away from the freezer compartment and avoid placing them directly against the back wall of the refrigerator where temperatures may drop below recommended levels.
Room temperature allowances before use (single-dose devices):
Wegovy: Up to 28 days at temperatures up to 86°F (30°C)
Trulicity: Up to 14 days at temperatures up to 86°F (30°C)
Mounjaro/Zepbound: Up to 21 days at temperatures up to 86°F (30°C)
After first use (multi-dose pens only):
Ozempic: Up to 56 days at room temperature or refrigerated
Victoza/Saxenda: Up to 30 days at room temperature or refrigerated
In warmer climates or during summer months, patients should be particularly cautious about leaving pens in hot cars, direct sunlight, or near heat sources. If room temperature storage is chosen, keep the pen in a cool, dry place away from direct heat and light.
During travel: Patients traveling with GLP-1 medications should use insulated medication travel cases, particularly during air travel or in warm weather. Pens should never be placed in checked luggage where they may freeze in the cargo hold. Transportation Security Administration (TSA) regulations permit passengers to carry injectable medications and associated supplies in carry-on luggage. For international travel, patients should carry a letter from their healthcare provider explaining the medical necessity of the medication.
General handling: Always replace the pen cap after each use to protect from light and maintain sterility. Never share pens between patients, even with a new needle, due to infection risk. Remove and safely dispose of needles immediately after each injection; do not store pens with needles attached, as this can cause medication leakage or air bubble formation.
Patients should inspect their GLP-1 medication before each use and recognize signs that indicate the medication should not be used. Visual inspection is the primary method for assessing medication integrity.
Normal appearance: GLP-1 solutions should be clear and colorless or almost colorless according to FDA-approved labeling. The solution should be free of particles and should not appear cloudy or contain floating material. Before each injection, hold the pen up to the light and examine the solution through the viewing window.
Warning signs requiring disposal:
Cloudiness or turbidity: If the normally clear solution appears cloudy, milky, or hazy, do not use it. This may indicate protein aggregation or bacterial contamination.
Discoloration: Any unusual color change suggests chemical degradation. Discard the pen immediately.
Visible particles: Floating particles, crystals, or sediment indicate the medication has degraded or been contaminated. Even small particles warrant disposal.
Freezing damage: If you know or suspect the pen was frozen, discard it even if it appears normal after thawing. Freezing causes irreversible structural damage to peptide medications.
Damaged pen: Cracks in the cartridge, a broken seal, or mechanical damage to the pen mechanism are safety concerns requiring disposal.
When to contact your healthcare provider: If you have used medication that you later discovered was expired, improperly stored, or visually abnormal, contact your provider. Monitor for signs of inadequate disease control, such as elevated blood glucose readings, increased thirst, frequent urination, or unexplained weight changes. Your provider may recommend more frequent glucose monitoring or temporary dose adjustments.
Patients should never attempt to use questionable medication. If you're concerned about a medication's appearance or storage history, contact your pharmacist or healthcare provider. If storage issues occurred before you received the medication, contact your pharmacy. For issues that occurred after receipt, contact the manufacturer's patient support line, though replacement is not guaranteed and depends on specific circumstances.
Yes, Ozempic can be used for up to 56 days after first use when stored properly at room temperature or refrigerated. The 28-day timeline applies to Wegovy (single-dose) when stored at room temperature before use, not Ozempic.
Using expired GLP-1 medication may result in reduced efficacy, potentially causing inadequate blood glucose control or diminished weight management effects. Contact your healthcare provider for guidance on monitoring and potential treatment adjustments.
Use insulated medication travel cases and carry GLP-1 medications in carry-on luggage to avoid freezing in cargo holds. Never leave pens in hot cars or direct sunlight, and consider carrying a letter from your healthcare provider for international travel.
All medical content on this blog is created using reputable, evidence-based sources and is regularly reviewed for accuracy and relevance. While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only.
This content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider with any medical questions or concerns. Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.
